Advancing Bispecifics for Combination Immunotherapy

First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics: What are the types of bispecifics and what are the limitations?What are the toxicity related side effects?What are teh next steps/levels for bispecifics?What does the future hold for bispecifics? Panelists include: Julie Bailis, PhD, AmgenRajkumar Ganesan, PhD, Janssen Research & DevelopmentDavid Schaer, PhD, Pfizer To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com